| dongtianzeng. Occurrence of No.12 lymph node micrometastasis in gastric cancer and its effect on clinicopathological parameters and prognosis. Oncol Transl Med, 2022, 8: 115-120. |
| 胃癌NO.12淋巴结微转移发生率及对患者临床病理参数、预后 的影响 |
| Occurrence of No.12 lymph node micrometastasis in gastric cancer and its effect on clinicopathological parameters and prognosis |
| Received:September 28, 2021 Revised:June 01, 2022 |
| DOI：10.1007/s10330-021-0526-6 |
| 中文关键词: 胃肿瘤； 淋巴转移； 微转移 |
| 英文关键词: gastric tumor; lymphatic metastasis; micrometastasis |
| 基金项目:河北省财政厅专科能力建设和带头人培养项目（361933） |
|
| Hits: 4362 |
| Download times: 5349 |
| 中文摘要: |
| 目的：探讨胃癌患者NO.12淋巴结微转移的发生率及与患者临床病理参数、预后的关系。方法：选择160例行胃癌切除术及淋巴结清扫的胃癌患者为研究对象，采用免疫组化法对常规病理学检测为阴性的No.12淋巴结切片进行微转移检测。同时，收集患者临床资料并随访，分析No.12淋巴结微转移的临床意义。结果：160例大体手术标本共检出370枚NO.12淋巴结。160例患者中，27例患者行常规病理检查时发现NO.12淋巴结阳性，阳性率为16.8%。对133例常规病理检查阴性的共308枚淋巴结进行免疫组化染色，又发现10例患者共17枚淋巴结阳性。综合二者的检查结果发现，160例患者患者中，共37例患者出现了NO.12淋巴结转移，阳性率为23.1%，比单纯常规病理检查阳性率高出6.3%。logistic多因素分析发现，浸润深度、其他组淋巴结转移、临床分期是影响NO.12淋巴结发生转移的独立性危险因素。全组患者平均随访时间79.3月,总体中位生存时间47.9月。No.12淋巴结阴性组患者生存时间（67.3±2.5）月,中位生存时间 73.2月；No.12 淋巴结阳性组生存时间为（28.4±5.4）月,中位生存时间31.3月，No.12 淋巴结阴性组患者生存时间明显长于阳性组(χ2＝12.75,P＝0.000)。结论：No.12淋巴结微转移是影响胃癌患者预后不良的信号，对可行根治性切除的胃癌患者建议行No.12淋巴结规范化清扫。 |
| 英文摘要: |
| Objective This study aimed to investigate the occurrence of No.12 lymph node micrometastasis in
patients with gastric cancer and its relationship with clinicopathological parameters and prognosis.
Methods A cohort of 160 gastric cancer patients who underwent gastrectomy and lymph node dissection
were selected as the research subjects. The immunohistochemical method was used to detect the
micrometastasis of No.12 lymph node sections with negative routine pathological detection. At the same
time, the clinical data of patients were collected and followed up to analyze the clinical significance of No.12
lymph node micrometastasis.
Results A total of 370 No.12 lymph nodes were detected in 160 surgical specimens. Among 160 patients,
27 patients were found to be positive for No.12 lymph nodes during routine pathological examination, with
a positive rate of 16.8%. A total of 308 lymph nodes from 133 patients with negative routine pathological
examinations were stained by immunohistochemistry. A total of 17 lymph nodes from 10 patients were
found to be positive. The results showed that 37 of the 160 patients had No.12 lymph node metastasis,
and the positive rate was 23.1%, which was 6.3% higher than that of routine pathological examination.
Logistic multivariate analyses showed that the depth of invasion, lymph node metastasis in other groups,
and clinical stage were independent risk factors for No.12 lymph node metastasis. The average follow-up
time was 79.3 months, and the overall median survival time was 47.9 months. The survival time of the
No.12 lymph node-negative group was 67.3 ± 2.5 ? months, the median survival time was 73.2 months;
the survival time of the No.12 lymph node-positive group was (28.4 ± 5.4) months, and the median survival
time was 31.3 months. The survival time of the No.12 lymph node-negative group was significantly longer
than that of the positive group (χ2 = 12.75, P = 0.000).
Conclusion No.12 lymph node micrometastasis is a signal affecting the prognosis of patients with gastric
cancer. Standardized dissection of No.12 lymph nodes is recommended for patients with gastric cancer
who can undergo radical resection. |
|
View Full Text
Download reader HTML全文 |
| Close |